149 related articles for article (PubMed ID: 38185032)
1. Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies.
Li Z; Follman K; Freshwater E; Engler F; Yel L
Int Immunopharmacol; 2024 Feb; 128():111447. PubMed ID: 38185032
[TBL] [Abstract][Full Text] [Related]
2. Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.
Li Z; Follman K; Freshwater E; Engler F; Yel L
J Clin Immunol; 2023 Nov; 43(8):2127-2135. PubMed ID: 37773562
[TBL] [Abstract][Full Text] [Related]
3. Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies.
Wiesik-Szewczyk E; Sołdacki D; Paczek L; Jahnz-Różyk K
Front Immunol; 2020; 11():981. PubMed ID: 32670265
[TBL] [Abstract][Full Text] [Related]
4. Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin.
Li Z; McCoy B; Engl W; Yel L
J Clin Immunol; 2021 Aug; 41(6):1331-1338. PubMed ID: 34036490
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases.
Li Z; Dumas T; Seth Berry N; McCoy B; Yel L
Int Immunopharmacol; 2021 Nov; 100():108044. PubMed ID: 34601202
[TBL] [Abstract][Full Text] [Related]
6. Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies.
Li Z; Follman K; Freshwater E; Engler F; Yel L
Int Immunopharmacol; 2022 Dec; 113(Pt A):109331. PubMed ID: 36461591
[TBL] [Abstract][Full Text] [Related]
7. Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations.
Ponsford M; Carne E; Kingdon C; Joyce C; Price C; Williams C; El-Shanawany T; Williams P; Jolles S
Clin Exp Immunol; 2015 Dec; 182(3):302-13. PubMed ID: 26288095
[TBL] [Abstract][Full Text] [Related]
8. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
[TBL] [Abstract][Full Text] [Related]
9. Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule.
Hustad NB; Degerud HM; Hjelmerud I; Fraz MSA; Nordøy I; Trøseid M; Fevang B; Aukrust P; Jørgensen SF
Front Immunol; 2021; 12():670547. PubMed ID: 34012453
[TBL] [Abstract][Full Text] [Related]
10. Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency.
Sidhu J; Rojavin M; Pfister M; Edelman J
Biol Ther; 2014 Dec; 4(1-2):41-55. PubMed ID: 25118975
[TBL] [Abstract][Full Text] [Related]
11. Clinical Practice Experience with HyQvia in Adults Using Alternative Dosing Regimens and Pediatric Patients: A Retrospective Study.
Wasserman RL;
Adv Ther; 2020 Apr; 37(4):1536-1549. PubMed ID: 32124273
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder.
Sarı G; Güven Bilgin B; Yılmaz E; Aytac G; Edeer Karaca N; Aksu G; Kutukculer N
Eur Ann Allergy Clin Immunol; 2021 Jul; 53(4):177-184. PubMed ID: 33191716
[No Abstract] [Full Text] [Related]
13. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.
Berger M; Rojavin M; Kiessling P; Zenker O
Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644
[TBL] [Abstract][Full Text] [Related]
15. Quality of Life Evaluation in Saudi Arabian Pediatric Patients with Primary Immunodeficiency Diseases Receiving 20% Subcutaneous IgG Infusions at Home.
Al-Saud B; AlRumayyan N; Alfattani A; Awwad SA; Al Saud D; Mohammed R; Albuhairi S; Elshorbagi S; Balhareth SS; Al-Dhekri H; Arnaout R; De Vol EB; Al-Mousa H
J Clin Immunol; 2023 Aug; 43(6):1360-1366. PubMed ID: 37145392
[TBL] [Abstract][Full Text] [Related]
16. Intravenous and subcutaneous immunoglobulin G replacement therapy.
Bonilla FA
Allergy Asthma Proc; 2016 Nov; 37(6):426-431. PubMed ID: 27931296
[TBL] [Abstract][Full Text] [Related]
17. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
[TBL] [Abstract][Full Text] [Related]
18. A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults.
Nagy A; Duff K; Bauer A; Okonneh F; Rondon JC; Yel L; Li Z
J Clin Immunol; 2023 Dec; 44(1):28. PubMed ID: 38129731
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency.
Visentin A; Molinari MC; Pravato S; Cellini A; Angotzi F; Cavaretta CA; Ruocco V; Imbergamo S; Piazza F; Proietti G; Mauro FR; Trentin L
Curr Oncol; 2022 Dec; 30(1):274-283. PubMed ID: 36661671
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases.
Navarro-Mora G; Alberti JJ; Mondou E; Vilardell D; Vicente Torres J; Ayguasanosa J; Páez A
Int Immunopharmacol; 2022 Mar; 104():108472. PubMed ID: 35008008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]